A Major Advance In Lung Cancer Treatment: Does Anyone Know About It?
This may be one of the most important advances in cancer treatment this year, and almost no one in the major media has reported it, as best I can tell: Osimertinib (trade name Tagrisso™) made a huge difference in outcomes for patients with early stage EGFR-biomarker positive lung cancer when used as adjuvant (preventive) therapy after primary treatment (complete surgical resection in all patients; adjuvant chemotherapy in some). When I say huge, I mean huge: EGFR+ patients with stage IB to IIIC non-small cell lung cancer (the most common type of lung cancer) had a close to 90% survival at… Read More »A Major Advance In Lung Cancer Treatment: Does Anyone Know About It?